Erxna Therapeutics Inc. has amended the consulting agreement for its Chief Financial Officer, Mark J. Keeley, to include a monthly cash stipend.

The Board of Directors approved the Consulting Agreement Addendum on November 14, 2026, effective November 9, 2026. The amendment supplements Mr. Keeley’s existing share-based compensation with a monthly cash payment of $5,000.

This cash compensation will be paid on the last day of each month. The amount for November 2026 is prorated to reflect the effective start date of the addendum. All other terms of the original Consulting Agreement, dated August 10, 2026, remain in full force and effect.

The full text of the addendum is filed as Exhibit 10.1 to the company’s Current Report on Form 8-K.